FSD Pharma (FSD Pharma) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. FSD Pharma's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. FSD Pharma's average Total Assets over the quarter that ended in Dec. 2023 was $18.21 Mil. Therefore, FSD Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

FSD Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for FSD Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Gross-Profit-to-Asset % Chart

FSD Pharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-4.50

FSD Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of FSD Pharma's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, FSD Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FSD Pharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, FSD Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where FSD Pharma's Gross-Profit-to-Asset % falls into.

FSD Pharma Gross-Profit-to-Asset % Calculation

FSD Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (38.411	+	17.475)	/ 2 )
	=	0	/	27.943
	=	0.00 %

FSD Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (18.942	+	17.475)	/ 2 )
	=	0	/	18.2085
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

FSD Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of FSD Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

FSD Pharma (FSD Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

0K9:Germany HUGE:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.